Respiratory panel multiplex PCR-12653

Test info

  
Respiratory panel multiplex PCR
  
12653
  
LAB12653
  
RESP
  
Respiratory panel
Respiratory viral panel
RPP
RVP
Viral
Viral panel

  
  • Adenovirus (AdV)
  • Bordetella parapertussis
  • Bordetella pertussis
  • Chlamydia pneumoniae
  • Coronavirus (CoV) 229E, HKU1, NL63, OC43
  • Human Rhinovirus (HRV)/Enterovirus (EV)
  • Human Metapneumovirus (hMPV)
  • Influenza A (Flu A) (subtypes H1, H1-2009, and H3)
  • Influenza B (Flu B)
  • Mycoplasma pneumoniae
  • Parainfluenza Virus 1 (PIV1)
  • Parainfluenza Virus 2 (PIV2)
  • Parainfluenza Virus 3 (PIV3)
  • Parainfluenza Virus 4 (PIV4)
  • Respiratory syncytial virus (RSV)
  • SARS-Cov-2
  

Triage of in-patients, emergency department/observation patients, and high-risk outpatients (immunocompromised or underlying cardiac/lung conditions) presenting with signs and symptoms of acute respiratory illness. Tests for 17 viral and 3 bacterial respiratory pathogens, however, does NOT detect MERS (Middle Eastern Respiratory Syndrome) or SARS (Severe Acute Respiratory Syndrome).

Ambulatory patients should have targeted testing for respiratory pathogens if indicated.

  

This assay does not detect MERS (Middle Eastern Respiratory Syndrome) or SARS (Severe Acute Respiratory Syndrome).

The detection of viral and bacterial nucleic acid is dependent upon proper specimen collection, handling, transportation, storage and preparation. Failure to observe proper procedures in any one of these steps can lead to incorrect results. There is a risk of false positive or false negative values resulting from improperly collected, transported or handled specimens.

A negative panel result does not exclude the possibility of viral or bacterial infection. Negative test results may occur from the presence of sequence variants (or mutation) in the region targeted by the assay, the presence of inhibitors, technical error, sample mix-up, an infection caused by an organism not detected by the panel, or lower respiratory tract infection that is not detected by a nasopharyngeal swab specimen. Test results may also be affected by concurrent antiviral/antibacterial therapy or levels of organism in the specimen that are below the limit of detection for the test. Negative results should not be used as the sole basis for diagnosis, treatment, or other patient management decisions.

Specimen

  
Nasopharyngeal (NP) swab
  
  

Nasopharyngeal (NP) swab collection:

  1. Tip the patient’s head back.
  2. Gently insert the NP swab into the nostril parallel to the palate (not upwards) until resistance is encountered or the distance is equivalent to that from the ear to the nostril of the patient, indicating contact with the nasopharynx.   
    1. If any resistance is met in the passageways, do not force the swab; back off and try reinserting it at a different angle, closer to the floor of the nasal canal, or try the other nostril.
  3. Gently rub and roll the swab for 10-15 seconds while the swab is in contact with the nasopharyngeal wall.
  4. The CDC recommends leaving the swab in place for several seconds to absorb secretions.
  5. Slowly remove the swab and place in the transport medium.
  6. Break the swab shaft so that it fits into the medium container and recap tightly.
  7. Label the specimen appropriately. Document the source “NP” on the label.

New England Journal of Medicine video on NP swab collection: Nasopharyngeal Swab Collection Video

 

  

BD Universal Viral transport media (UTM)

 

  

Viral transport media (VTM), M4, M4RT or M5

Buffered saline (PBS)

  

Viral transport media (VTM), M4, M4RT or M5

Buffered saline (PBS)

 

  

Refrigerated (preferred) - 3 days

Ambient - 4 hours

Frozen (<-15°C) - 30 days

  
  • Improper label (unlabeled or mislabeled)
  • Time delay between time of collection and receipt of specimen
  • Improper transport container
  • Improper transport temperature
  • Interfering substances
  • Inappropriate specimen type
  • Leaking container

Performance

  
AHL - Microbiology: M
  
Daily
  
2.5 hours after receipt at the Allina Health Central Laboratory
  

Real time Polymerase Chain Reaction (RT-PCR)

Clinical and Interpretive info

  

Not detected

  

Detected:  The assay(s) for the organism were POSITIVE.

Not detected:  The assay(s) for the organism were NEGATIVE.

Invalid:  Failure of assay controls.  Unable to determine detected (positive) or not detected (negative) for the target organism(s).

The results of this test should not be used as the sole basis for diagnosis, treatment, or other management decisions.

Organism (abbreviation)

Classification

(Genome type)

Season of Highest

Incidencea

Most Commonly Infected

Demographic

Adenovirus (AdV)

Adenovirus (DNA)

Late winter to early

summer

All ages,

immunocompromised

Bordetella parapertussis

Bacterium (DNA) 

No peak season 

All ages 

Bordetella pertussis

Bacterium (DNA)

No peak season

All ages

Chlamydophila pneumoniae

Bacterium (DNA)

No peak season

Older children, young adults,

immunocompromised

Coronavirus (CoV) 229E,HKU1, NL63, OC43

Coronavirus (RNA)

Winter, spring

Children, adults

Enterovirus (EV)

Picornavirus(RNA)

Summer, early fall

All ages

Human Rhinovirus (HRV)

Picornavirus (RNA)

Fall, spring

All ages

Human Metapneumovirus

(hMPV)

Paramyxovirus (RNA)

Winter, early spring

Children

Influenza A (Flu A)

(subtypes H1, H1-2009, and H3)

Orthomyxovirus (RNA)

 

Winter

All ages, 5-20 % of US

populationb

Influenza B (Flu B)

Orthomyxovirus (RNA)

Winter

All ages, 5-20 % of US

Populationb

Mycoplasma pneumoniae

Bacterium (DNA)

Outbreaks most common

in summer, outbreak

periodicity 4 – 7 years

Older children, young adults

Parainfluenza Virus 1 (PIV1)

Paramyxovirus (RNA)

Fall, periodicity of 1-2

years

Infants, young children,

immunocompromised

Parainfluenza Virus 2 (PIV2)

Paramyxovirus (RNA)

Fall, periodicity of 1-2

years

Infants, young children,

immunocompromised

Parainfluenza Virus 3 (PIV3)

Paramyxovirus (RNA)

Spring, summer

Infants, young children,

Immunocompromised

Parainfluenza Virus 4 (PIV4)

      Paramyxovirus (RNA)

Unknown

All ages

Respiratory Syncytial Virus

(RSV)

Paramyxovirus (RNA)

Winter, varies by

location[

Children, older adults

 

SARS-CoV-2

Coronavirus (RNA)

Novel pandemic Coronavirus

All ages

a Based on North American seasons

b During annual Influenza epidemics, 5-20% of the population is affected with upper respiratory tract infections with rapid onset of fever.

Billing

  
0099U
0202U
  
Yes
  

Tracking

  
10/08/2015
  
12/20/2023
  
12/15/2023